Last reviewed · How we verify
Sodium Hyaluronate 1%
Sodium Hyaluronate 1% is a marketed product by Ziv Medical Center, currently holding a position in the therapeutic landscape without specified primary indications or revenue data. The key strength of the drug lies in its composition patent, which is set to expire in 2028, providing a period of exclusivity. The primary risk is the potential increase in competition post-patent expiry, which could impact market share and profitability.
At a glance
| Generic name | Sodium Hyaluronate 1% |
|---|---|
| Also known as | ARTHREASE, Euflexxa |
| Sponsor | Ziv Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- USC-Exos in Corpus Spongiosum Reconstruction for Hypospadias (NA)
- Clinical Investigation on Lips Treated With HA-filler (NA)
- Hyaluronic Acid and Albumin-PRF in Non-Surgical Periodontal Therapy (NA)
- A Clinical Investigation of the Decoria® Aesthetic Group (DAG) for Correction of Nasolabial Folds (NLF) (NA)
- A Post-market-clinical Follow-up Investigation of Safety and Performance by Decoria® Voluma (NA)
- Phase 3 Pivotal Trial Comparing CARTISTEM® and Surgical Comparator for Knee Cartilage Lesions and Osteoarthritis (PHASE3)
- Efficacy and Safety of Vaginal Radiofrequency for Vulvovaginal Atrophy in Breast Cancer Patients (NA)
- Efficacy of Therapy With PRP Injections Versus HA in Patients With Advanced Grade of GONArthrosis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |